Rating Rationale
March 20, 2018 | Mumbai
Kwality Pharmaceuticals Limited
Rating outlook revised to 'Positive'; ratings reaffirmed
 
Rating Action
Total Bank Loan Facilities Rated Rs.35 Crore
Long Term Rating CRISIL BB+/Positive (Outlook revised from 'Stable' and rating reaffirmed)
Short Term Rating CRISIL A4+ (Reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has revised its rating outlook on the long-term bank facilities of Kwality Pharmaceuticals Limited (KPPL) to 'Positive' from 'Stable', and reaffirmed the rating at 'CRISIL BB+'; the short-term rating has been reaffirmed at 'CRISIL A4+'.

The outlook revision reflects expected strengthening of business risk profile, driven by improvement in scale of operations and operating profitability. For six months ending September 2017 in fiscal 2018, turnover was Rs 61.5 crore and operating margin 10.6%; against full-year operating income of Rs 96.26 crore and operating margin of 10.0% in fiscal 2017. Sales and margin improved on account of increased sales in the domestic market. The company's working capital cycle is expected to slightly improve over the medium term driven by the reduction in execution of government orders. The outlook revision also factors in comfortable financial risk profile on account of management's stance to fund any capital expenditure (capex) majorly through own funds.

The ratings continue to reflect KPPL's established position in the formulations segment and comfortable financial risk profile. These strengths are partially offset by modest scale of operations in the competitive pharmaceutical industry and working capital-intensive operations.

Key Rating Drivers & Detailed Description
Strengths
* Established player in the formulations segment: Over the past three decades, the company has developed a diverse product portfolio of more than 2000 drugs in the form of tablets, capsules, small volume liquid injections, liquid syrups, dry syrups, dry injections, dental cartridges, and suppositories. It has also added new products such as anti-cancer drugs and penicillin antibiotics. Furthermore, clientele is diverse, with domestic sales having contributed around 51% of total turnover in fiscal 2017, sales deemed export 12%, and export 37%

* Above average financial risk profile: Gearing was above average at 0.74 time as on March 31, 2017, and is expected to remain below 1 time over the medium term on account of comfortable networth. However, capex size and its funding mix will remain a key rating sensitivity factor. Debt protection metrics have also remained above average. Liquidity is adequate due to high cash accrual against term debt repayment.

Weaknesses:
* Modest scale of operations in competitive segment: With turnover of Rs 96.26 crore in fiscal 2017, scale remains small in the intensely competitive pharmaceutical formulations segment. However, operating revenue is expected to improve over the medium term, aided by a healthy order book of Rs 130-140 crore.

* Working capital-intensive operations: Gross current assets were 187 days as on March 31, 2017, due to high receivables of 87 days.
Outlook: Positive

CRISIL believes KPPL's business profile will continue to benefit over the medium term from its improving revenues and operating margins.  The rating may be upgraded in case of substantial improvement in revenue, profitability, and cash accrual; and a stable capital structure. The outlook may be revised to 'Negative' if decline in scale of operations or profitability, large, debt-funded capex, or stretched working capital cycle weakens financial risk profile.

About the Company

Set up in 1980 as a partnership firm and reconstituted as a private limited company in 1983, Amritsar-based KPPL manufactures formulations in the form of injectables, tablets, capsules, and syrups. It has two units, one each in Amritsar and Kangra (Himachal Pradesh), with capacity to produce 3.5 million and 8.5 million tablets per day, respectively. The Kangra unit commenced production in October 2008. 

Key Financial Indicators (Standalone)
Particulars Unit 2017 2016
Revenue Rs cr 96.26 75.53
Profit After Tax (PAT) Rs cr 3.44 0.83
PAT Margins % 3.6 1.1
Adjusted debt/adjusted networth Times 0.74 0.59
Interest coverage Times 5.09 5.03

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of instrument Date of allotment Coupon
rate (%)
Maturity date Issue
size
(Rs cr)
Rating assigned with outlook
NA Cash Credit NA NA NA 10 CRISIL BB+/Positive
NA Letter of credit & Bank Guarantee NA NA NA 3 CRISIL A4+
NA Long Term Loan NA NA Mar-2023 2 CRISIL BB+/Positive
NA Proposed Cash Credit Limit NA NA NA 5 CRISIL BB+/Positive
NA Proposed Export Packing Credit NA NA NA 8 CRISIL A4+
NA Proposed Letter of Credit & Bank Guarantee NA NA NA 5 CRISIL A4+
NA Proposed Long Term Bank Loan Facility NA NA NA 2 CRISIL BB+/Positive
Annexure - Rating History for last 3 Years
  Current 2018 (History) 2017  2016  2015  Start of 2015
Instrument Type Quantum Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  27  CRISIL BB+/Positive/ CRISIL A4+    No Rating Change    No Rating Change  07-11-16  CRISIL BB+/Stable/ CRISIL A4+    No Rating Change  CRISIL BB/Stable/ CRISIL A4+ 
Non Fund-based Bank Facilities  LT/ST  CRISIL A4+    No Rating Change    No Rating Change    No Rating Change    No Rating Change  CRISIL A4+ 
Table reflects instances where rating is changed or freshly assigned. 'No Rating Change' implies that there was no rating change under the release.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Cash Credit 10 CRISIL BB+/Positive Cash Credit 10 CRISIL BB+/Stable
Letter of credit & Bank Guarantee 3 CRISIL A4+ Letter of credit & Bank Guarantee 3 CRISIL A4+
Long Term Loan 2 CRISIL BB+/Positive Long Term Loan 2 CRISIL BB+/Stable
Proposed Cash Credit Limit 5 CRISIL BB+/Positive Proposed Cash Credit Limit 5 CRISIL BB+/Stable
Proposed Export Packing Credit 8 CRISIL A4+ Proposed Export Packing Credit 8 CRISIL A4+
Proposed Letter of Credit & Bank Guarantee 5 CRISIL A4+ Proposed Letter of Credit & Bank Guarantee 5 CRISIL A4+
Proposed Long Term Bank Loan Facility 2 CRISIL BB+/Positive Proposed Long Term Bank Loan Facility 2 CRISIL BB+/Stable
Total 35 -- Total 35 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
Rating Criteria for the Pharmaceutical Industry
CRISILs Approach to Recognising Default
CRISILs Bank Loan Ratings
CRISILs Criteria for rating short term debt
The Rating Process

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Jyoti Parmar
Media Relations
CRISIL Limited
D: +91 22 3342 1835
B: +91 22 3342 3000
 jyoti.parmar@crisil.com

Nitin Kansal
Director - CRISIL Ratings
CRISIL Limited
D:+91 124 672 2154
nitin.kansal@crisil.com


Himank Sharma
Associate Director - CRISIL Ratings
CRISIL Limited
D:+91 124 672 2152
Himank.Sharma@crisil.com


Ojaswini Gupta
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 124 672 2181
Ojaswini.Gupta@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is an agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 100,000 customers.

We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY NOTICE

CRISIL respects your privacy. We use your contact information, such as your name, address, and email id, to fulfil your request and service your account and to provide you with additional information from CRISIL and other parts of S&P Global Inc. and its subsidiaries (collectively, the “Company) you may find of interest.

For further information, or to let us know your preferences with respect to receiving marketing materials, please visit https://www.crisil.com/en/home/privacy-and-cookie-notice.html. You can view the Company’s Customer Privacy at https://www.spglobal.com/corporate-privacy-policy

Last updated: April 2016


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL